Why the study?
Does dobutamine infusion change high energy phosphate concentrations in normal subjects and patients with dilated cardiomyopathy?
Does dobutamine infusion change high energy phosphate concentrations in normal subjects and patients with dilated cardiomyopathy?
Inotropic stimulation with dobutamine does not significantly alter myocardial high energy phosphate concentrations in normal subjects or those with compensated dilated cardiomyopathy.
Dobutamine preserves myocardial energetics in compensated DCM; leaves open effects in decompensated states or other phenotypes.
In order to determine if an increase in myocardial oxygen consumption is accompanied by changes in high energy phosphates in normal subjects and patients with dilated cardiomyopathy, phosphorus-31 spectra were acquired under resting conditions and during dobutamine infusion. In seven normal subjects, dobutamine raised the rate-pressure product to 226% of control. The ratio of PCr/ATP was 1.86 +/- 0.17 (mean +/- SE) under resting conditions and 1.90 +/- 0.22 (P = 0.44) with dobutamine infusion. In eight patients with dilated cardiomyopathy, dobutamine raised the rate-pressure product to 161% of control. As in the normal subjects, the ratio of PCr/ATP under resting conditions (1.63 +/- 0.24) was unchanged during dobutamine infusion (1.57 +/- 0.24, P = 0.38). These data indicate that increases in cardiac work do not have a major effect on high energy phosphate concentrations in normal subjects or in patients with clinically compensated dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Schaefer et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: